Phase II Ergebnisse und News

• MK 49 Mio. $
  
• Q3/18 Cash ~34 Mio. $
  
• Q3/18 Verlust ~adj. 10 Mio. $
  

"Genocea expects that its existing cash and cash equivalents are sufficient to support its operating expenses and capital expenditure requirements into the fourth quarter of 2019.

Genocea continues to explore strategic alternatives for GEN-003, its Phase 3-ready investigational immunotherapy for the treatment of genital herpes."

ir.genocea.com/news-releases/...-2018-financial-and-operating

• MK ~60 Mio. $
  
• Loss from operations ~9 Mio. $
  
• Cash 26 Mio. $
  

"Genocea expects that its existing cash and cash equivalents are sufficient to support its operations into the first quarter of 2020.

Genocea continues to explore strategic alternatives for GEN-003, its Phase 3-ready investigational immunotherapy for the treatment of genital herpes.

Genocea’s Board of Directors has adopted a resolution approving and recommending that stockholders support a proposal in the company’s upcoming proxy statement to effect a reverse stock split of the company’s issued and outstanding common stock, if necessary, to maintain the company’s NASDAQ Capital Market listing."

ir.genocea.com/news-releases/...-results-and-announces-hiring

Genocea meldet Zahlen für Q1/19

• keine Umsätze
  
• Verlust 16 Mio. $
  
• Cash 29 Mio. $
  
• MK 84 Mio. $
  

ir.genocea.com/news-releases/...-including-first-quarter-2019

• am 22. Mai gab es einen 8/1 Split
  
• Kurs nach dem Split ~4,75$
  
• Daten zu GEN-009
  

ir.genocea.com/news-releases/...emonstrates-best-class-immune

• würde mich nicht wundern, wenn hier bald ein Offering kommen würde
  

seekingalpha.com/news/...ve-genminus-009-data-cancer-patients

Tadaa, hier ist das Offering:

• 10,5 Mio. Aktien zu je 3,50 $ = rund 37 Mio. $
  

ir.genocea.com/news-releases/...-public-offering-common-stock

Genocea meldet Zahlen für Q2/19

• keine Umsätze
  
• op. Verlust 10 Mio. $
  
• Cash 59 Mio. $
  
• MK 83 Mio. $
  

ir.genocea.com/news-releases/...including-second-quarter-2019